Amneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension
Go back to Amneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension| AmerElite Solutions, Inc. New (NASDAQ: AMRX) | Delayed: 16.95 +0.08 (0.47%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $16.87 | 52 Week High | $0.19 | |||
| Open | $17.00 | 52 Week Low | $0.07 | |||
| Day High | $17.11 | P/E | N/A | |||
| Day Low | $16.73 | EPS | $-0.01 | |||
| Volume | 389,365 | |||||
